- This topic has 0 replies, 1 voice, and was last updated 2 years, 9 months ago by .
Viewing 0 reply threads
-
Posts
-
-
Viewing 0 reply threads
- You must be logged in to reply to this topic.
Home › Forums › Restricted content › Treatments for the motor complications of PD
Our invited review article on non-dopaminergic treatments for motor complications in Parkinson’s disease has just been published on-line: https://doi.org/10.1016/j.neuropharm.2022.109027
This is a comprehensive review covering scientific rationale, pre-clinical research, and clinical studies about a vast range of receptor targets (5-HT1A/1B, NMDA, AMPA, mGlu5, mGlu4, adenosine A2a). We also review a number of compounds that have reached the stage of clinical development, including compounds with complex pharmacological properties (such as amantadine, safinamide, zonisamide, pridopidine, mesdopetam). We conclude with some reflections on caveats and opportunities for present and future translational research in this area.
The journal has provided us with a personalized URL providing 50 days’ free access to our article. Anyone clicking on this link before May 06, 2022 will be taken directly to the final version of the article on ScienceDirect, which they are welcome to read or download. No sign up, registration or fees are required.
https://authors.elsevier.com/a/1elxG6T90t3ZZ
Enjoy the reading!
Angela
